阿法替尼在重度经治ERBB2突变阳性晚期NSCLC中的活性:全球命名患者使用计划发现
中位治疗失败时间(TTF)为2.9个月,8例(29%)TTF超过1年;客观缓解率19%(3/16),疾病控制率69%(11/16)。在12例明确突变类型的患者中,10例为外显子20 p.A775_G776insYVMA插入,该亚组中位TTF 9.6个月,客观缓解率33%(2/6),疾病控制率100%(6/6)。结论提示阿法替尼在ERBB2突变阳性NSCLC中具有活性,识别特定突变亚组可能优化ErbB2靶向治疗结局。
要点
- 阿法替尼在重度经治ERBB2突变阳性晚期NSCLC中显示活性,中位TTF 2.9个月。
- 外显子20 p.A775_G776insYVMA插入亚组中位TTF 9.6个月,DCR 100%。
- 识别特定ERBB2突变亚型可能有助于优化ErbB2靶向治疗。
核心结论
- 阿法替尼在ERBB2突变阳性晚期NSCLC中具有临床活性。
- 识别特定突变亚组如外显子20 p.A775_G776insYVMA插入可能优化ErbB2靶向治疗结局。
研究设计与样本
- 患者接受阿法替尼30-50 mg/d compassionate治疗,在常规临床实践中用药。
主要发现
- 中位治疗失败时间(TTF)为2.9个月,8例(29%)TTF超过1年。
- 客观缓解率19%(3/16),疾病控制率69%(11/16)。
- 12例明确ERBB2突变类型的患者中,10例为外显子20 p.A775_G776insYVMA插入,其中4例(40%)阿法替尼治疗超过1年。
- 该插入亚组中位TTF 9.6个月,客观缓解率33%(2/6),疾病控制率100%(6/6)。
关键数值与推荐
- ERBB2突变阳性NSCLC患者接受阿法替尼30-50 mg/d治疗。
- 外显子20 p.A775_G776insYVMA插入亚组:中位TTF 9.6个月,ORR 33%(2/6),DCR 100%(6/6)。
临床怎么用
- 对于重度经治的ERBB2突变阳性晚期NSCLC,阿法替尼可作为治疗选择之一。
- 建议检测ERBB2突变具体类型,外显子20 p.A775_G776insYVMA插入患者可能从阿法替尼治疗中更多获益。
局限性
- 疗效和安全性为回顾性评估,非前瞻性随机对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor tyrosine kinase 2 (ERBB2) mutation; there is no approved targeted treatment for this subgroup. METHODS: Patients with stage IV NSCLC that progressed after clinical benefit on erlotinib/gefitinib and/or had activating EGFR or ERBB2 mutations, had exhausted other treatments, and were ineligible for afatinib trials were enrolled in a named patient use program, receiving afatinib 30 to 50 mg/d on a compassionate basis within routine clinical practice. Efficacy and safety were retrospectively assessed in the subgroup with ERBB2 mutation-positive NSCLC. RESULTS: Twenty-eight heavily pretreated patients in the named patient use program had a documented ERBB2 mutation by local testing. Median time-to-treatment failure (TTF; time from treatment initiation to discontinuation for any reason) was 2.9 months; eight patients (29%) had TTF greater than 1 year. Objective response rate was 19% (3 of 16 patients with response data achieved partial response) and disease control rate (DCR) was 69% (11 of 16). Among 12 patients for whom type of ERBB2 mutation was specified, 10 had a p.A775_G776insYVMA insertion in exon 20, four of whom (40%) remained on afatinib for more than 1 year. This subgroup had median TTF of 9.6 months, objective response rate of 33% (two of six), and disease control rate of 100% (six of six). CONCLUSIONS: This analysis of patients treated in clinical practice provides further evidence of the activity of afatinib in ERBB2 mutation-positive NSCLC, and suggests that identification of specific subgroups with certain mutations, such as p.A775_G776ins/YVMA insertion in exon 20, could help optimize outcomes with ErbB2-targeted treatment.
引用
- Peters S, Curioni-Fontecedro A, Nechushtan H, et al. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. J Thorac Oncol. 2018. PMID: 30096481. doi:10.1016/j.jtho.2018.07.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。